Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
- Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants on December 17, 2018 at 5:44 pm
“The DNA encodes a nuclease, such as CRISPR/Cas9, which makes the gene edit. The problem with conventional gene editing is that DNA can integrate randomly into the genome ... combining its leading gen... […]
- Calyxt (CLXT) Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants on December 17, 2018 at 12:32 pm
“The DNA encodes a nuclease, such as CRISPR/Cas9, which makes the gene edit. The problem with conventional gene editing is that DNA can integrate randomly into the genome, creating off-target effects. ... […]
- Scientists discover rules that determine precision of CRISPR/Cas9 genome editing in human cells on December 13, 2018 at 10:19 pm
Scientists at the Francis Crick Institute have discovered a set of simple rules that determine the precision of CRISPR/Cas9 genome ... application of the technology has been hindered by the assumption ... […]
- Scientists crack the CRISPR code for precise human genome editing on December 13, 2018 at 8:05 am
Illustration of the CRISPR/Cas9 genome editing system ... rational application of the technology has been hindered by the assumption that the outcome of genome editing is unpredictable, resulting ... […]
- ERS Genomics and Lonza Enter Into CRISPR/Cas9 Technology Licensing Deal on December 12, 2018 at 10:59 pm
ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. Lonza will have the abi... […]
- Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population on December 6, 2018 at 4:30 am
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has ... […]
- Researchers discover mechanism disrupting CRISPR-Cas9 gene editing on December 5, 2018 at 6:30 am
Researchers at Delft University of Technology have now ... Normally, gene editing experts using CRISPR-Cas9 can change part of the genome of a cell by introducing a new sequence of DNA. […]
- Global Genome Editing Market 2017-2018 & 2025: Opportunities in Emerging Markets For Precision and Regenerative Medicines on November 21, 2018 at 3:43 pm
Whereas, perception of the people for genetic alteration and stringent regulation are likely to impact the growth of the genome editing market. Nevertheless, the trend of the usage of CRISPR Cas9 tech... […]
- CRISPR Cas9 Genome Editing Market Worth $5.3 Billion by 2025 on November 19, 2018 at 6:39 am
This report focuses on the CRISPR-Cas9 genome editing tools including its technology, market, and patent landscape. The report forecasts the sizes and trends of the global market as well as its sub-se... […]
via Google News and Bing News